[1] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease: the major impact of china. Hepatology,2015,60:2099-2108.
[2] Friedman SL,Neuschwander-Tetri BA,Rinella M,et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med,2018,24:908-922.
[3] Park CC,Nguyen P,Hernandez C,et al.Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastro-enterology,2016,152:598-607.
[4] Di Martino M,Koryukova K,Bezzi M,et al. Imaging features of non-alcoholic fatty liver disease in children and adolescents. Children (Basel),2017,4. pii:E73.
[5] Hsu C,Caussy C,Imajo K,et al. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol,2018,pii:S1542-3565(18)30613-X.
[6] Chalasani N,Younossi Z,Lavine JE,et al.The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,2018,67:328-357.
[7] Stepanova M,Rafiq N,Makhlouf H,et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease(NAFLD). Diq Dis Sci,2013,58:3017-3023.
[8] Ratziu V,Goodman Z,Sanyal A. Current efforts and trends in the treatment of NASH.J Hepatol,2015,62(1 Suppl):S65-75.
[9] Tan CH,Al-Kalifah N,Ser KH,et al.Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score. Surg Obes Relat Dis,2018,pii:S1550-7289(18)30292-2.
[10] Goh GB,Schauer PR,McCullough AJ. Considerations for bariatric surgery in patients with cirrhosis. World J Gastroenterol,2018,24:3112-3119.
[11] Iogna Prat L,Tsochatzis EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones,2018,17:219-229.
[12] Wong VW. Current prevention and treatment options for NAFLD. Adv Exp Med Biol, 2018,1061:149-157.
[13] Lewis JD,Habel LA,Quesenberry CP,et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA,2015,314:265-277.
[14] Sumida Y,Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol,2017,53:362-376.
[15] Sato K,Gosho M,Yamamoto T,et al.Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition,2015,31: 923-930.
[16] Armstrong MJ,Hull D,Guo K,et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol,2016,64:399-408.
[17] Issa D,Wattacheril J,Sanyal AJ. Treatment options for nonalcoholic steatohepatitis-a safety evaluation.Expert Opin Drug Saf,2017,16:903-913.
[18] Sarna LK,Siow YL,O K. The CBS/CSE system: a potential therapeutic target in NAFLD? Can J Physiol Pharmacol,2015,93:1-11.
[19] Jain MR,Giri SR,Bhoi B,et al. Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models. Liver Int,2018,38:1084-1094.
[20] Younossi ZM,Stepanova M,Lawitz E,et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int,2018,38:1849-1859.
[21] Chen Q,Liu M,Yu H,et al. Scutellaria baicalensis regulates FFA metabolism to ameliorate NAFLD through the AMPK-mediated SREBP signaling pathway. J Nat Med, 2018,72:655-666.
[22] Lee JH,Baek SY,Jang EJ,et al.Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Chem Biol interacti,2018,289:68-74.
[23] Zhang Y,Tang K,Deng Y,et al. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats. Biomed Pharmacother,2018,102:1025-1036. |
